Takeda Pharmaceuticals U.S.A. Inc.
1 Takeda Pkwy
About Takeda Pharmaceutical
Millennium Pharmaceuticals was established in 1993 as a genomics company, applying world-class molecular biology and genomic technologies to the discovery and development of new therapies in a broad spectrum of diseases. Over time we evolved into a fully integrated biopharmaceutical company.
In May 2008, Millennium was acquired by Takeda Pharmaceutical Company Limited in Japan and became known as Millennium: The Takeda Oncology Company (Millennium), a wholly-owned subsidiary of Takeda that served as the organization’s global center of excellence in oncology.
The combination of oncology resources resulted in a robust pipeline that addresses a broad range of cancers. Our focus is to improve the treatment of cancer, which gives us an important oncology mission to deliver extraordinary medicines to patients with cancer worldwide through our science, innovation and passion, toward an ultimate goal and aspiration to cure cancer.
In May 2013, the decision was made to fully integrate Millennium into the global Takeda R&D engine to maximize the resources available from the broader Takeda organization and to realize greater operational efficiencies. The R&D and G&A functions in Boston became known publically as Takeda Pharmaceuticals International Co. The oncology Commercial, Business Development and Patient Advocacy divisions continue to operate as Millennium: The Takeda Oncology Company.
At Takeda and Millennium, we want to exceed expectations in terms of progress against cancer, distinguishing ourselves within the research-based biopharmaceutical community. We’re prepared to deliver on this goal by focusing on novel or best-in-class drug candidates, and cultivating the brightest talent. This puts Takeda on an exciting path toward global oncology leadership.
We help drive and accelerate the progress that continually is being made against cancer; these advances, sometimes big breakthroughs and sometimes incremental, make a real difference in the lives of patients. We won’t be satisfied until cures are found and the threat is removed. People who battle cancer deserve no less.
Our goal also is to provide patients and people close to them with easily understandable information about the diseases our products treat, as well as other relevant information and service resources. We also provide information about our investigational drugs that are approaching or in development, our clinical trials, and what patients, caregivers and healthcare providers need to know about our assistance and access programs for any drug we currently market. We work toward our goals with the same urgency for patients that we would for our families. We strive to earn the respect and admiration of the global oncology community by delivering significant progress against cancer while living our core values.
The people and culture at Takeda and Millennium make all the difference.
Our work is more than a job. We are entrepreneurial about both our work and achieving progress. We focus on what’s important and timely decision-making.
As a site based in New England, we enjoy our local community and contribute in many ways to local business, social and environmental causes. We offer a broad range of opportunities for campus-based employees to participate. We also involve ourselves on a corporate level in matters of social responsibility.
June 12, 1781
Founder: Chobei Takeda
CEO: Christophe Weber
CMO (Medical) and CSO (Scientific): Andrew Plump
CFO: James Kehoe
Please click here for Takeda job opportunities.
Tweets by Takeda
935 articles with Takeda Pharmaceutical
The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, alternately supportive and non-supportive of efforts to eliminate the Affordable Care Act, better known as Obamacare.
Takeda Pharmaceutical Company Limited today announced the results of the shareholder votes at its Extraordinary General Meeting of Shareholders (“EGM”) regarding the recommended acquisition of Shire plc.
Although it was probably not in serious peril, shareholders of Japan’s Takeda Pharmaceutical voted to approve the acquisition of Dublin’s Shire. The deal is currently valued at $58 billion.
Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas
-Data Presented in Oral Session with Simultaneous Publication in The Lancet-
Seattle Genetics and Takeda show off the impressive survival data that prompted the FDA to give approval to Adcetris for this indication.
Significant Milestone in Proposed Acquisition of Shire
Takeda to Present Positive Data from TOURMALINE-MM3, First Pivotal Phase 3 Placebo Controlled Trial Evaluating Proteasome Inhibitor Treatment in Maintenance Setting
Maintenance Therapy with NINLARO™ (ixazomib) Improved Progression-Free Survival in Adult Patients with Multiple Myeloma Following Autologous Stem Cell Transplant
European Commission Approves ALUNBRIG® (brigatinib) for ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib, Advancing Treatment Paradigm in Europe
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Commission (EC) granted marketing authorization for ALUNBRIG (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib
A Small Group of Pharma Companies Is Making the Bulk of Medicines Necessary for Developing Countries
11/21/2018There are 7 billion people in the world. Of those, 5 billion have access to life-saving medications, while 2 billion do not. That is a gap that pharmaceutical companies can help close through increased R&D programs, logistical initiatives and the lowering of prices, the Access to Medicine Foundat...
Takeda Pharmaceutical Company Limited (“Takeda”) announces that it has received clearance from the European Commission (the “EC”) for the proposed acquisition of Shire plc (“Shire”) announced on May 8, 2018 (the “Acquisition”).
After announcing a potential snag with the European Commission last month, Takeda said this morning that it received clearance for its acquisition of Shire. The clearance is conditional on addressing overlaps in the companies’ inflammatory bowel disease businesses.
According to the American Cancer Society, almost 601,000 people in the U.S. died of cancer in 2017. The two most common types of cancer are lung cancer and breast cancer, followed by colorectal cancer, prostate cancer and stomach cancer.
Takeda Announces Publication of Circular and Notice of Extraordinary General Meeting of Shareholders in Relation to the Proposed Acquisition of Shire
Reaffirms Strategic and Financial Rationale for the Acquisition
Pharma giant Takeda Pharmaceutical is looking to begin 2019 with a bang – closing its $62 billion acquisition of Shire plc by Jan. 8. This morning Takeda announced that it will hold an investor vote next month on the planned acquisition in order to swiftly move and finalize the deal.
Boston Business Journal recently created a list of 15 Massachusetts life science companies that in their third-quarter reports, allocated the highest percentage of total costs to research and development. Here’s a look.
Nektar Therapeutics, based in San Francisco, and New York-based Pfizer are teaming up to evaluate combination regimens in several cancer settings. Those include metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and heck (SCCHN).
Crescendo Biologics Ltd today announces that Takeda Pharmaceutical Company Limited (Takeda), has exercised an option under its existing, multi-target collaboration and license agreement.
Acting on an option out of 2016 collaboration deal, Japan’s Takeda Pharmaceutical licensed Humabodies directed to one of its oncology targets from Cambridge, UK’s Crescendo Biologics.
Takeda to Present Data During 60th American Society of Hematology Annual Meeting on Wide Array of Treatment Needs for Blood Cancers
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it will present a total of 18 company-sponsored abstracts at the 60th American Society of Hematology (ASH) Annual Meeting taking place in San Diego from December 1 to 4, 2018.
Shares of Denali Therapeutics are up more than 10 percent in premarket trading after the company announced it has inked a collaborative deal with Sanofi to develop potential treatments for neurological and systemic inflammatory diseases.